The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

Inclusion Criteria: * Hospitalized patients with severe COVID-19 (5 point on NIH 8-point ordinal scale). * Male or female adult ≥18 years of age at time of enrollment; * Biological samples (not limited to any specific type) collected within 72 hours before randomization is laboratory-confirmed as SARS-CoV-2 infection (PCR or antigen-based diagnostic tests); * ≤ 10 days since symptoms of COVID-19 onset. Exclusion Criteria: * Patients who need non-invasive ventilation or high flow oxygen (i.e., 6 point on the 8-point ordinal scale); * Patients with critical COVID-19; * Patients with Severe COVID-19 who received convalescent plasma or COVID-19 vaccine, or anti-SARS-CoV-2 spike (S) protein targeted therapy; * Alanine-amino transferase (ALT) or aspartate transaminase (AST) is 5 times higher than the upper limit of the normal value; * Estimated glomerular filtration rate (eGFR) \<30 mL/min or on dialysis {eGFR calculated by Cockcroft-Gault formula (Cockcroft DW, 1976), Male: CrCL (mL/min) = \[(140 - age) × weight (kg)\] × 1/ \[SCr (mg/dL) × 72\]; Female: CrCL (mL/min) = \[(140 - age) × weight (kg)\] × 0.85/ \[SCr (mg/dL) × 72\]}.